KYORIN Pharmaceutical Co., Ltd. (TYO:4569)

Market Cap	85.37B
Revenue (ttm)	121.55B
Net Income (ttm)	3.85B
Shares Out	57.45M
EPS (ttm)	66.96
PE Ratio	22.19
Forward PE	20.48
Dividend	52.00 (3.50%)
Ex-Dividend Date	Mar 28, 2025

Volume	78,800
Average Volume	140,145
Open	1,471.00
Previous Close	1,475.00
Day's Range	1,471.00 - 1,492.00
52-Week Range	1,331.00 - 1,840.00
Beta	-0.05
RSI	51.99
Earnings Date	May 12, 2025

About KYORIN Pharmaceutical

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Lyfuna for cough treatment; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex and Mometasone KYORIN, which are used as allergic rhinitis th...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1923
• Employees: 2,042
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4569

Financial Performance

In 2023, KYORIN Pharmaceutical's revenue was 119.53 billion, an increase of 5.53% compared to the previous year's 113.27 billion. Earnings were 5.32 billion, an increase of 12.68%.